Table 1.
Major Clinico-Pathological Characteristics of 121 BC Patients with CWR
| Items | n (%) |
|---|---|
| Median age (years)a | 49 (29–82)b |
| T stage (cm) | |
| T1 | 8 (6.6) |
| T2 | 61 (50.4) |
| T3 | 13 (10.7) |
| T4 | 20 (16.5) |
| No data | 19 (15.7) |
| N stage | |
| N0 | 37 (30.6) |
| N1 | 31 (25.6) |
| N2 | 11 (9.1) |
| N3 | 32 (26.4) |
| No data | 10 (8.3) |
| Metastasis | |
| Yes | 61 (50.4%) |
| No | 60 (49.6%) |
| Histological type | |
| Invasive ductal carcinoma | 101 (83.5) |
| Other invasive carcinoma | 14 (11.6) |
| No data | 6 (4.9) |
| Histological grade | |
| I | 0 (0) |
| II | 49 (40.5) |
| III | 30 (24.8) |
| No data | 42 (34.7) |
| HR statusa | |
| Positive | 59 (48.8) |
| Negative | 58 (47.9) |
| No data | 4 (3.3) |
| HER2b | |
| Positive | 51 (42.2) |
| Negative | 62 (51.2) |
| No data/uncertain | 8 (6.6) |
| Received therapy strategies | |
| Chemotherapy | 96 (79.3) |
| Endocrine therapy | 39 (32.2) |
| Targeted therapy | 3 (2.5) |
| Radiotherapy | 27 (22.3) |
Notes: aOnset age; bRange of age.
Abbreviations: HR, hormone receptor; HER2, human epidermal receptor-2.